Abstract:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 2019 (COVID-19), has evoked a global pandemic. Due to its rapid transmission rate and severity of illness, the urgent need for the expedited design and development of effective therapeutics is evident, Computer-Aided Drug Design (CADD) methods have been employed to accelerate the drug development process. More than 30000 medication compounds were subjected to virtual screening for SARS-CoV-2 main protease. The top 10 molecules based on the binding affinity scores were chosen to subject extra-precision docking and explored their pharmacokinetic properties to validate whether they bind well to the SARS-CoV-2 main protease. The results indicated that the binding free energy values between Mpro and these ligands predominantly fall within the range of -7 to -8 kcal/mol, suggesting relatively stable interactions between the ligands and the protein target. Significant contributions to the binding of most small molecules were identified through molecular dynamics simulations and MM/PBSA (Molecular Mechanics/Poisson-Boltzmann Surface Area) analyses, with residues such as His164, Glu166, and Asp187 found to be crucial. Therefore, these residues have been recognized as potential targets for drug design. In summary, ZINC000306568896 exhibited the optimal binding free energy of -28.68 kcal/mol, and was evaluated as the lead compound with the strongest binding affinity in this series. Its favourable pharmacokinetic properties and stable association with the active site suggest that it is a promising lead inhibitor for SARS-CoV-2. These results demonstrated that this ligand has great potential to be an ideal lead inhibitor for SARS-CoV-2, and to expedite the development of therapeutic interventions against COVID-19.

A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

Discovery of All-d-Peptide Inhibitors of SARS-CoV-2 3C-like Protease

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease

In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus

Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-2

Computational Discovery of SARS-CoV-2 Main Protease Inhibitors Via a Virtual Screening, Molecular Docking, Molecular Dynamics and MM/PBSA Calculations-Driven Approach

The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation

Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling

Identification of possible SARS-CoV-2 main protease inhibitors: in silico molecular docking and dynamic simulation studies

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity

Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation

An in-silico evaluation of COVID-19 main protease with clinically approved drugs

Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2

In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro)

Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease

Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach

Discovery of SARS-CoV-2 3CLPro Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Protein–Ligand Interactions